Although investor concerns about the MedTech Sector have been based on expected declines in obesity rates with the surging adoption of GLP-1s, IQVIA MedTechs analysis of the data tells a different story, overall, that - to date - obesity diagnoses remain stable during the rise of GLP-1 uptake as depicted below: As a result, the resilience of obesity diagnosis occurring despite the rising uptake of GLP-1s should serve as a positive general signal for MedTech industry players to counter investor concerns about the potential of reduced demand, or that the demand may be net-neutral, rather than a sudden decline
Significantly, both echidna and platypus GLP-1 were not degraded by human DPP-4 (Fig
The Solution at P.O.W
Zepbound is approved for weight loss
This integration ensures that patients receive their medications promptly and conveniently, directly to their doorstep
At this stage, patients commonly experience reduced snacking, improved portion control, and longer periods of fullness after meals